BridgeBio Pharma (BBIO) Other financing activities (2018 - 2025)
BridgeBio Pharma recorded quarterly Other financing activities of $600000.0 in Q4 2025, up 105.72% quarter-over-quarter from -$10.5 million in Q3 2025.
BridgeBio Pharma's Other financing activities history runs 8 years deep, the most recent figure standing at $600000.0 for Q4 2025.
- In Q4 2025, Other financing activities changed N/A year-over-year to $600000.0; the TTM figure through Mar 2026 stood at -$7.9 million (down 297.92% YoY), while the FY2025 annual figure was $2.2 million, changed N/A from the prior year.
- Other financing activities came in at $600000.0 for Q4 2025 at BridgeBio Pharma, up from -$10.5 million in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $4.9 million in Q3 2023 to a low of -$16.1 million in Q4 2021.
- A 5-year average of -$279421.1 and a median of $800000.0 in 2025 frame the typical range for Other financing activities.
- Across the five-year window, Other financing activities jumped 36500.0% in 2022 and plunged 826.54% in 2025, its largest moves.
- BridgeBio Pharma's Other financing activities stood at -$16.1 million in 2021, then surged by 98.24% to -$283000.0 in 2022, then slumped by 183.04% to -$801000.0 in 2023, then surged by 280.15% to $1.4 million in 2024, then sank by 58.42% to $600000.0 in 2025.
- According to Business Quant data, Other financing activities over the past three periods registered $600000.0, -$10.5 million, and $2.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | BridgeBio Pharma | 12.91 Bn | 11.98 Bn | 184.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 600,000.00 |
| Dec 31, 2025 | 600,000.00 |
| Sep 30, 2025 | -10.48 Mn |
| Sep 30, 2025 | -10.48 Mn |
| Jun 30, 2025 | 2.00 Mn |
| Jun 30, 2025 | 2.00 Mn |
| Mar 31, 2025 | 800,000.00 |
| Mar 31, 2025 | 800,000.00 |
| Sep 30, 2024 | 1.44 Mn |
| Sep 30, 2024 | 1.44 Mn |
| Jun 30, 2024 | 1.74 Mn |
| Jun 30, 2024 | 1.74 Mn |
| Mar 31, 2024 | 536,000.00 |
| Mar 31, 2024 | 536,000.00 |
| Dec 31, 2023 | -801,000.00 |
| Dec 31, 2023 | -801,000.00 |
| Sep 30, 2023 | 4.91 Mn |
| Sep 30, 2023 | 4.91 Mn |
| Jun 30, 2023 | 1.20 Mn |
| Jun 30, 2023 | 1.20 Mn |
| Mar 31, 2023 | 1.81 Mn |
| Mar 31, 2023 | 1.81 Mn |
| Dec 31, 2022 | -283,000.00 |
| Dec 31, 2022 | -283,000.00 |
| Sep 30, 2022 | 596,000.00 |
| Sep 30, 2022 | 596,000.00 |
| Jun 30, 2022 | 366,000.00 |
| Jun 30, 2022 | 366,000.00 |
| Mar 31, 2022 | 966,000.00 |
| Mar 31, 2022 | 966,000.00 |
| Dec 31, 2021 | -16.06 Mn |
| Dec 31, 2021 | -16.06 Mn |
| Sep 30, 2021 | 3.70 Mn |
| Sep 30, 2021 | 3.70 Mn |
| Jun 30, 2021 | 1,000.00 |
| Jun 30, 2021 | 1,000.00 |
| Mar 31, 2021 | 1.65 Mn |
| Mar 31, 2021 | 1.65 Mn |
| Dec 31, 2020 | 11.06 Mn |
| Dec 31, 2020 | 11.06 Mn |
| Sep 30, 2020 | 243,000.00 |
| Sep 30, 2020 | 243,000.00 |
| Jun 30, 2020 | 691,000.00 |
| Jun 30, 2020 | 691,000.00 |
| Mar 31, 2020 | 529,000.00 |
| Mar 31, 2020 | 529,000.00 |
| Dec 31, 2019 | 18.75 Mn |
| Dec 31, 2019 | 18.75 Mn |
| Sep 30, 2019 | 2.12 Mn |
| Sep 30, 2019 | 2.12 Mn |
| Jun 30, 2019 | 2.12 Mn |
| Jun 30, 2019 | 2.12 Mn |
| Mar 31, 2019 | 936,000.00 |
| Mar 31, 2019 | 936,000.00 |
| Dec 31, 2018 | 24,000.00 |
| Dec 31, 2018 | 24,000.00 |
| Sep 30, 2018 | 326,000.00 |
| Sep 30, 2018 | 326,000.00 |
| Jun 30, 2018 | 325,000.00 |
| Jun 30, 2018 | 325,000.00 |